From monoclonals to bispecific T cell engagers: the evolving antibody-based therapy landscape in acute myeloid leukemia - Poll - MDSpire

From monoclonals to bispecific T cell engagers: the evolving antibody-based therapy landscape in acute myeloid leukemia

  • By

  • Milad Rasouli

  • Marie Dalem

  • Marc H.G.P. Raaijmakers

  • Peter D. Katsikis

  • Stefan J. Erkeland

  • June 1, 2026

  • 0 min

Share

Original Source(s)

From monoclonals to bispecific T cell engagers: the evolving antibody-based therapy landscape in acute myeloid leukemia

  • by Milad Rasouli, Marie Dalem, Marc H.G.P. Raaijmakers, Peter D. Katsikis, Stefan J. Erkeland

  • June 1, 2026

Related Content

Data requirements of an informative, directive, and preventive mobile health application for gastric cancer

MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial

Prospective phase II study of frontline Helicobacter pylori eradication therapy for early-stage extragastric mucosa-associated lymphoid tissue lymphoma